REG - Hutchmed China Ltd - Board of Directors and Board Committee Membership

HUTCHMED (China)Announcement

12/05/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230512:nRSL2450Za&default-theme=true

RNS Number : 2450Z  Hutchmed (China) Limited  12 May 2023

HUTCHMED Announces Board of Directors and Board Committee Membership

 

 

Hong Kong, Shanghai & Florham Park, NJ  - Friday, May 12, 2023: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM:HCM, HKEX:13) refers to its announcement on May 10, 2023 of the
appointment of Professor Solange Peters as an Independent Non-executive
Director, member of the Technical Committee and member of the Audit Committee
of the Company with effect from the conclusion of the annual general meeting
of the Company to be held on May 12, 2023 ("AGM"). The Company today announces
that the effective date of such appointments will be deferred until a later
date to be announced by the Company.

 

The Company also announces that Professor Mok Shu Kam, Tony will be appointed
as member of the Audit Committee of the Company at the conclusion of the AGM,
subject to Professor Mok being re-elected as a Director by the shareholders at
the AGM.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among other things,
the risk that current or future appointees to HUTCHMED's board of directors
are not effective in their respective positions, the difficulty in locating
and recruiting suitable candidates for its board of directors and the
management difficulties which may arise from changes in HUTCHMED's board of
directors. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the U.S. Securities and Exchange Commission, on AІM and with The
Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to
update or revise the information contained in this announcement, whether as a
result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

 Investor Enquiries
 Mark Lee, Senior Vice President                                  +852 2121 8200
 Annie Cheng, Vice President                                      +1 (973) 306-4490

 Media Enquiries
 Americas - Brad Miles,                                           +1 (917) 570 7340 (Mobile) / bmiles@s (mailto:bmiles@soleburystrat.com)

Solebury Strategic Communications                               oleburystrat (mailto:bmiles@soleburystrat.com) .com
                                                                  (mailto:bmiles@soleburystrat.com)
 Europe - Ben Atwell / Alex Shaw,                                 +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                                                  +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                  (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                                        +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                  (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon  +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMGAUPWUMP